DOCSLIB.ORG

2016 Annual Information Form

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2016 Annual Information Form TABLE OF CONTENTS EXPLANATORY NOTES 3 Glossary................................................................................................................................................................................... 3 Trademarks.............................................................................................................................................................................. 3 Currency.................................................................................................................................................................................. 3 Market Data............................................................................................................................................................................. 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION 4 CORPORATE STRUCTURE 7 Name, Address and Incorporation........................................................................................................................................... 7 Governance.............................................................................................................................................................................. 7 Reorganization ........................................................................................................................................................................ 7 GENERAL DEVELOPMENT OF THE BUSINESS 8 DESCRIPTION OF THE BUSINESS 14 Intercorporate Relationships ................................................................................................................................................... 14 REPORTABLE SEGMENT SUMMARY TABLE 15 COMPETITION 15 CONCORDIA INTERNATIONAL 15 Overview ................................................................................................................................................................................. 15 Products................................................................................................................................................................................... 16 Asset Impairments................................................................................................................................................................... 16 Product Development and Production..................................................................................................................................... 17 Sales and Distribution ............................................................................................................................................................. 18 Key Markets, Growth and Marketing Strategy ....................................................................................................................... 18 United Kingdom...................................................................................................................................................................... 18 Intellectual Property Matters................................................................................................................................................... 19 Regulatory Matters.................................................................................................................................................................. 19 Launch of New Products......................................................................................................................................................... 20 CONCORDIA NORTH AMERICA 20 Overview ................................................................................................................................................................................. 20 Products................................................................................................................................................................................... 20 Asset Impairments................................................................................................................................................................... 21 Product Development and Production..................................................................................................................................... 21 Sales and Distributions............................................................................................................................................................ 22 Key Markets, Growth and Marketing Strategy ....................................................................................................................... 22 Intellectual Property Matters................................................................................................................................................... 24 Regulatory Matters.................................................................................................................................................................. 24 ORPHAN DRUGS 25 Overview ................................................................................................................................................................................. 25 Market Overview..................................................................................................................................................................... 25 PDT with Photofrin®.............................................................................................................................................................. 26 Existing Indications................................................................................................................................................................. 26 Other Developments................................................................................................................................................................ 26 DESCRIPTION OF CAPITAL STRUCTURE 27 Common Shares ...................................................................................................................................................................... 27 Stock Option Plan ................................................................................................................................................................... 27 Long Term Incentive Plan....................................................................................................................................................... 28 DIVIDEND POLICY 31 RATINGS 31 S&P ......................................................................................................................................................................................... 33 Moody’s................................................................................................................................................................................... 33 MARKET FOR SECURITIES 34 Trading Price and Volume....................................................................................................................................................... 34 Prior Sales ............................................................................................................................................................................... 34 DIRECTORS AND EXECUTIVE OFFICERS OF THE CORPORATION 37 Directors and Executive Officers, Positions and Security Holdings....................................................................................... 37 Shareholdings of Directors and Executive Officers................................................................................................................ 38 Biographies.............................................................................................................................................................................. 38 Corporate Cease Trade Orders or Bankruptcies...................................................................................................................... 40 Penalties or Sanctions.............................................................................................................................................................. 40 Individual Bankruptcies .......................................................................................................................................................... 40 Conflicts of Interest................................................................................................................................................................. 40 LEGAL PROCEEDINGS AND REGULATORY MATTERS 40 INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS 42 PROMOTER 42 AUDIT COMMITTEE 42 Reliance on Certain Exemptions............................................................................................................................................. 42 Audit Committee Oversight .................................................................................................................................................... 43 Pre-Approval Policies and Procedures.................................................................................................................................... 43 External Auditor Service Fees................................................................................................................................................. 43 MATERIAL CONTRACTS 43 INTEREST OF EXPERTS 45 TRANSFER AGENT AND REGISTRAR 45 RISK FACTORS 45 Risk Factors Related to
Load more

Recommended publications
  • Advz Md&A Q2 2020
    SECOND QUARTER ENDED JUNE 30, 2020 MANAGEMENT’S DISCUSSION AND ANALYSIS August 12, 2020 Table of Contents 1 Management's Discussion and Analysis 2 2 Business Overview, Corporate Strategy and Segments 3 3 Recent Events 5 4 Results of Operations 8 5 Segment Performance 11 6 Corporate and Other Costs 14 7 Selected Quarterly Financial Information 17 8 Balance Sheet Analysis 19 9 Liquidity 21 10 Lending Arrangements and Debt 23 11 Contractual Obligations 24 12 Related Party Transactions 25 13 Non-IFRS Financial Measures 26 14 Critical Accounting Estimates 28 15 Contingencies 29 16 Outstanding Share Data 32 17 Control Environment 33 18 Forward-looking Statements 34 1 Management's Discussion and Analysis The following Management’s Discussion and Analysis ("MD&A") summarizes ADVANZ PHARMA Corp. Limited's (formerly known as ADVANZ PHARMA Corp.) (the "Company", "ADVANZ PHARMA", and together with its subsidiaries, the "Group", or "we" or "us" or "our") consolidated operating results and cash flows for the three and six month periods ended June 30, 2020 with the comparative prior periods, and the Company’s balance sheet as at June 30, 2020 and December 31, 2019. The MD&A was prepared as of August 12, 2020 and should be read in conjunction with the unaudited condensed interim consolidated financial statements and the notes thereto as at and for the three and six month periods ended June 30, 2020 and the consolidated financial statements and MD&A for the year ended December 31, 2019. Financial information in this MD&A is based on financial statements that have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and amounts are stated in thousands of United States Dollars ("USD"), which is the reporting currency of the Company, unless otherwise noted.
    [Show full text]
  • Confidential Information Memorandum
    Joint Lead Arrangers and Joint Bookrunners Confidential Information Memorandum $560,000,000 Credit Facilities $200,000,000 Multi-Currency First Lien Revolving Credit Facility $360,000,000 EUR First Lien Term Loan B To Finance the Acquisition of ADVANZ PHARMA Corp. Limited by Nordic Capital March 2021 ADVANZ PHARMA Leading Specialty Pharmaceutical Company with a Strategic Focus on Complex Medicines in Europe Century Gothic RGB 7, 92, 103 ADVANZ PHARMA Confidential Information Memorandum Table of Contents 1. Administrative Infor mation 3 1.1. Special Notice 4 1.2. Important Notice 5 1.3. Company Authorisation Letter 11 1.4. Contact Information 14 1.5. Indicative Timetable 19 2. Transaction Overview 20 2.1. Introduction 21 2.2. Sources & Uses and Pro Forma Capitalisation 22 2.3. Summary Terms and Conditions 23 2.4. Indicative Structure Post Closing (Simplified) 24 2.5. Company Snapshot 25 2.6. Summary Historical Financials 26 2.7. Market Backdrop 27 2.8. Ov erview of Nordic Capital 28 2.9. Nordic Capital Inv estment Thesis 29 3. Key Credit Highlights 30 3.1. Attractiv e and Resilient Sector with Structural and Demographic Tailwinds Supporting Growth Trends 32 3.2. Highly-Div ersified Portfolio with Limited Concentration 33 3.3. Niche and Essential medicines with Long Prescription History and Stable Demand 34 3.4. Near-term Pipeline of Differentiated and Value Add Products to Deliv er Organic Growth 36 3.5. Lean, Asset-Light Operating Model Underpinned by Differentiated India Centre of Excellence 38 3.6. Strong Margins Coupled with High Cash Flow Generation 39 3.7.
    [Show full text]
  • Final Disclosure Materials
    Confidential Lender Materials Confidential – For Advisor Eyes Only Confidential DISCLAIMER This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or in any other jurisdiction and shall not constitute an offer, solicitation or sale in any jurisdiction in which or to any person to whom such an offer, solicitation or sale would be unlawful. The information in this presentation is intended to be a summary of certain information relating to Concordia International Corp. (“Concordia” or the “Company”) as of May 2, 2018 or such other dates as indicated herein and does not purport to be a complete description of Concordia. It is provided for information purposes only and is subject to change without notice. Notice regarding future-oriented financial information: To the extent any forward-looking statements or forward-looking information in this presentation or oral statements made in connection herewith constitute future-oriented financial information or financial outlooks within the meaning of applicable securities laws, such information is being provided to demonstrate the potential financial performance of Concordia and readers are cautioned that this information may not be appropriate for any other purpose and that they should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks (collectively, “FOFI”), as with forward-looking statements and forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out below under “Notice regarding forward-looking statements”, a number of which are beyond the Company’s control.
    [Show full text]
  • ADVANZ in Brief
    Advanz Pharma Leading Specialty Pharmaceutical Company with a Strategic Focus on Complex Medicines in Europe Investor Presentation – March 2021 Disclaimer IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to this document, the accompanying oral and/or video presentation of this document by the Group (as defined below) or any person on behalf of the Group, the question-and-answer session that follows such oral or video presentation, hard copies of this document or any material distributed at, or in connection with, that presentation (collectively, the “Presentation”) and you are therefore advised to read this disclaimer carefully before making any use of the information in the Presentation. References to “Recipient” shall mean you and any natural or legal person who has lawfully gained access to this Presentation. The Presentation has been prepared by Cidron Aida Finco S.à r.l. (the “Issuer” and, together with ADVANZ PHARMA Corp. Limited (“Advanz”) and its consolidated subsidiaries, the “Group”) in connection with certain financial transactions (the “Transactions”), including the proposed offering of notes (the “Notes”). The Presentation has not been independently verified by any of Goldman Sachs International, Barclays Bank PLC (together, the “Global Coordinators), J.P. Morgan AG, Jefferies International Limited, Jefferies GmbH, Morgan Stanley & Co. International plc, RBC Europe Limited and Intesa Sanpaolo S.p.A. (collectively with the Global Coordinators, the “Initial Purchasers”). By attending the meeting at which the Presentation is made, dialing into the teleconference during which the Presentation is made or reading the Presentation, you will be deemed to have agreed to all of the restrictions that apply with regard to the Presentation and acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.
    [Show full text]
  • 2015 Annual Information Form March 23, 2016
    2015 ANNUAL INFORMATION FORM MARCH 23, 2016 TABLE OF CONTENTS EXPLANATORY NOTES ...................................................................................................................................... 3 Glossary ....................................................................................................................................................................................................... 3 Trademarks .................................................................................................................................................................................................. 3 Currency ....................................................................................................................................................................................................... 3 Market Data................................................................................................................................................................................................. 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION.............................................. 4 CORPORATE STRUCTURE ................................................................................................................................. 6 Name, Address and Incorporation ......................................................................................................................................................... 6 Governance ................................................................................................................................................................................................
    [Show full text]
  • The Pharma 1000 Top Global Pharmaceutical Company Report
    The Pharma 1000 Top Global Pharmaceutical Company Report September 2020 © 2020. All rights reserved. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. 1 Table of Contents The Evolving Global Pharmaceutical Sector 5 The Biotechnology Sector 16 The Branded Pharma Sector 24 The Generic Drug Sector 34 Financial Players in Pharma: Private Equity and Royalty Firms 38 Top Players by Country and Segment 44 The Pharma 1000 List 55 About Torreya and Acknowledgements 96 2 Torreya’s Pharma 1000 Report . Torreya is a globally active investment bank focused on the pharmaceutical sector. We began to track assets, people and companies in the industry with our own database in 2012. In “The Pharma 1000” report, we leverage our database to identify the top 1000 companies by value today. This presentation provides a summary of the key findings of the report. We hope to give you a greater sense of the global scale of the pharmaceutical industry and its extraordinary growth. We also wish to recognize the companies that appear on the Pharma 1000 list for the accomplishment of becoming a top company in one of the world’s most important and challenging Download the Full Report industries. 3 Torreya Pharma 1000 Study Approach . We identified approximately 30,000 pharmaceutical companies in 2012. Our team studied these companies and pulled out the active operating companies in ethical pharmaceuticals which had a tangible basis for valuation.
    [Show full text]
  • Our Story the Resilience, Agility and Shared Values of Our People Has Seen Us Thrive Despite the Highly Competitive and Challenging Business Environment We Operate In
    Our Story The resilience, agility and shared values of our people has seen us thrive despite the highly competitive and challenging business environment we operate in. We have set ourselves an ambitious five-year corporate goal to be the ‘go to partner’ when commercialising complex medicines in European hospitals, and I am confident we will achieve this as a united and committed team. Graeme Duncan, CEO Introduction Welcome to ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe that is committed to improving the lives of patients by enhancing the critical medicines they depend on. We could not do this without the resilience and entrepreneurial spirit of our people, the successful collaboration with our partners, and intrinsic guidance of our values to help us achieve our purpose while becoming a truly dynamic, progressive company in the process. Graeme Duncan, CEO Our Purpose Our purpose is simple – to improve the lives of patients by enhancing the critical medicines they depend on, broadening patient access and optimising health outcomes. Our Goal To become the ‘go to partner’ when commercialising complex medicines in European hospitals. Our Values Our values reflect who we are and what we stand for. Having a purpose, goal and values would mean nothing, however, if we didn’t have the people to bring them to life, to share the journey and vision of building a company we believe in. From London to Mumbai, Helsingborg to Sydney and Geneva to Chicago, resilience and common values have united ADVANZ PHARMA, regardless of geography or remote working situation.
    [Show full text]
  • ADVANZ PHARMA CORP. LIMITED 2019 ANNUAL INFORMATION FORM March 25, 2020 TABLE of CONTENTS
    ADVANZ PHARMA CORP. LIMITED 2019 ANNUAL INFORMATION FORM March 25, 2020 TABLE OF CONTENTS EXPLANATORY NOTES ............................................................................................................................................ 5 Glossary ..................................................................................................................................................................... 5 Trademarks ................................................................................................................................................................ 5 Currency .................................................................................................................................................................... 5 Market Data ............................................................................................................................................................... 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION .................................................... 6 CORPORATE STRUCTURE ..................................................................................................................................... 11 Name, Address and Incorporation ........................................................................................................................... 11 Internal Reorganizations .......................................................................................................................................... 11 Governance .............................................................................................................................................................
    [Show full text]
  • Beyond Fulfilment “Beyond Fulfilment Isn’T Just Our Brand Essence
    beyond fulfilment “Beyond fulfilment isn’t just our brand essence. It encompasses everything we do from producing market defining solutions to how we communicate with our clients and each other. It is what helps define ADVANZ PHARMA®” Graeme Duncan Chief Executive Officer It is with great pleasure that I introduce you to our new company, ADVANZ PHARMA® and the great opportunities that lie ahead as we look to shape the specialty off patent sector. ADVANZ PHARMA® is the culmination of decades of developing and supplying specialty generics and legacy brands with renewed innovation and investment in the future. Our teams are world class pharmaceutical experts with extensive global capabilities and the vision to re- energise, optimise and add value to our extensive diverse portfolio and growing pipeline. We define our brand essence asbeyond fulfilment which underpins our attitude and our intent. Beyond fulfilmentencompasses everything we do and everything we aspire to be, from producing market defining solutions to how we communicate with our clients and each other. It is what helps define ADVANZ PHARMA®. We are ready to advance into this exciting future with the introduction of new innovation, new products and new thinking, all designed to develop and enhance the outcomes for patients and healthcare providers around the world. ADVANZ PHARMA® is open for business. OUR STRATEGY ADVANZ PHARMA® has a PLAN that is based around two strategic guiding policies designed to drive future growth. We support these policies with two operational imperatives that set out the key action areas that we will deliver on as we commence this new exciting journey.
    [Show full text]
  • Management Discussion and Analysis – 17 March 2021
    2020 ANNUAL MANAGEMENT’S DISCUSSION AND ANALYSIS March 17, 2021 Table of Contents 1 Management's Discussion and Analysis......................... 2 2 Business Overview, Corporate Strategy and Segments. 3 3 Recent Events.................................................................. 5 4 Results of Operations...................................................... 9 5 Segment Performance.................................................... 11 6 Corporate and Other Costs............................................. 13 7 Selected Annual Financial Information........................... 16 8 Selected Quarterly Financial Information....................... 17 9 Balance Sheet Analysis.................................................... 19 10 Liquidity........................................................................... 21 11 Lending Arrangements and Debt.................................... 23 12 Contractual Obligations.................................................. 24 13 Related Party Transactions............................................. 25 14 Non-IFRS Financial Measures.......................................... 26 15 Critical Accounting Estimates......................................... 28 16 Contingencies.................................................................. 31 17 Outstanding Share Data.................................................. 35 18 Control Environment....................................................... 36 19 Forward-looking Statements.......................................... 37 1 Management's Discussion
    [Show full text]
  • Advz Md&A Q3 2020
    THIRD QUARTER ENDED SEPTEMBER 30, 2020 MANAGEMENT’S DISCUSSION AND ANALYSIS November 6, 2020 Table of Contents 1 Management's Discussion and Analysis 2 2 Business Overview, Corporate Strategy and Segments 3 3 Recent Events 5 4 Results of Operations 8 5 Segment Performance 11 6 Corporate and Other Costs 14 7 Selected Quarterly Financial Information 17 8 Balance Sheet Analysis 19 9 Liquidity 21 10 Lending Arrangements and Debt 23 11 Contractual Obligations 24 12 Related Party Transactions 25 13 Non-IFRS Financial Measures 26 14 Critical Accounting Estimates 28 15 Contingencies 29 16 Outstanding Share Data 32 17 Control Environment 33 18 Forward-looking Statements 34 1 Management's Discussion and Analysis The following Management’s Discussion and Analysis ("MD&A") summarizes ADVANZ PHARMA Corp. Limited's (formerly known as ADVANZ PHARMA Corp.) (the "Company", "ADVANZ PHARMA", and together with its subsidiaries, the "Group", or "we" or "us" or "our") consolidated operating results and cash flows for the three and nine month periods ended September 30, 2020 with the comparative prior periods, and the Company’s balance sheet as at September 30, 2020 and December 31, 2019. The MD&A was prepared as of November 6, 2020 and should be read in conjunction with the unaudited condensed interim consolidated financial statements and the notes thereto as at and for the three and nine month periods ended September 30, 2020 and the consolidated financial statements and MD&A for the year ended December 31, 2019. Financial information in this MD&A is based on financial statements that have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and amounts are stated in thousands of United States Dollars ("USD"), which is the reporting currency of the Company, unless otherwise noted.
    [Show full text]
  • Important Notice This Offering Is
    IMPORTANT NOTICE THIS OFFERING IS AVAILABLE ONLY TO INVESTORS WHO ARE EITHER (1) QUALIFIED INSTITUTIONAL BUYERS (‘‘QIBs’’) WITHIN THE MEANING OF RULE 144A (‘‘RULE 144A’’) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ‘‘SECURITIES ACT’’), OR (2) PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) AND WHO ARE OUTSIDE THE UNITED STATES IN ACCORDANCE WITH REGULATION S (‘‘REGULATION S’’) UNDER THE SECURITIES ACT (AND, IF INVESTORS ARE RESIDENT IN A MEMBER STATE OF THE EUROPEAN ECONOMIC AREA (THE ‘‘EEA’’) OR THE UNITED KINGDOM, NOT A RETAIL INVESTOR). YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THE FOLLOWING APPLIES TO THE PRELIMINARY OFFERING MEMORANDUM FOLLOWING THIS NOTICE (THE ‘‘OFFERING MEMORANDUM’’), AND YOU ARE THEREFORE ADVISED TO READ THIS CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE OFFERING MEMORANDUM. IN ACCESSING THE OFFERING MEMORANDUM, YOU AGREE TO BE BOUND BY THE FOLLOWING TERMS AND CONDITIONS, INCLUDING ANY MODIFICATIONS TO THEM ANY TIME YOU RECEIVE ANY INFORMATION FROM US AS A RESULT OF SUCH ACCESS. THE OFFERING MEMORANDUM HAS BEEN PREPARED IN CONNECTION WITH THE PROPOSED OFFERING AND SALE OF THE SECURITIES DESCRIBED THEREIN. THE OFFERING MEMORANDUM AND ITS CONTENTS ARE CONFIDENTIAL AND SHOULD NOT BE DISTRIBUTED, PUBLISHED OR REPRODUCED (IN WHOLE OR IN PART) OR DISCLOSED BY RECIPIENTS TO ANY OTHER PERSON. NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR ANY OTHER JURISDICTION AND THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S.
    [Show full text]